Spotlight On... Texas Tech team experiments with CRISPR/Cas9 upgrade; New drug candidate spotted for acute lymphoblastic leukemia; Temple researchers spotlight heart damage mechanism; and more...

Texas Tech researchers say they were able to improve on CRISPR/Cas9 technology by "tweaking" the sequence of the single guide RNA template. "The extent of the improvement in knockout efficiency with these changes was striking," Haoquan Wu says. "This is going to help reduce concerns that knockout experiments might not work, and also significantly increase the efficiency of more challenging editing procedures like gene deletion." Release

> Researchers at The Ottawa Hospital and the University of Ottawa say they have identified a new therapeutic candidate for acute lymphoblastic leukemia. Release

> Temple investigators are spotlighting a new mechanism involved in aldosterone-induced heart damage. Release

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.